PROTEINA Co., Ltd.
KKRX:46853043,450.00
KRW
+700.00
(+1.64%)
ISIN
KR7468530001
Return %
Stock
S&P 500
1Y
-8.62
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Tae-Young Yoon
- Full Time Employees
- 15
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Ace Techno Tower 8 #1301 Seoul SL South Korea 08380
- IPO Date
- Jul 29, 2025
- Website
- proteina.co.kr
- Similar Companies
- Business
- Proteina Co., Ltd. is a South Korean biotechnology company specializing in the development and commercialization of protein-protein interaction (PPI) profiling technology. The company offers advanced technology platforms for real-time detection and analysis of protein interactions at the single-molecule level, enabling insights into cancer signal pathway activation, drug efficacy prediction, and personalized drug resistance mechanisms. Its core products include the SPID technology and SPID platform for high-resolution protein interaction measurement, supporting applications in precision medicine, biomarker discovery, and therapeutic target identification. Proteina operates primarily in South Korea, targeting healthcare and pharmaceutical sectors, and serves researchers and clinicians seeking innovative solutions for disease diagnosis and drug development. Founded in 2015 and headquartered in Seoul, the company has made significant strides in biotechnology with cutting-edge protein interaction analytical tools. Recent developments include breakthrough research published in Nature Biomedical Engineering related to personalized treatment approaches for acute myeloid leukemia (AML). Proteina has also seen strategic interest and investment from major financial entities such as J.P. Morgan, bolstering its market position and accelerating its research and development efforts. These developments reflect Proteina’s continued expansion and leadership in protein interaction technology within the biotech industry. The company is led by CEO Tae-Young Yoon and continues to innovate in protein big data and precision biotechnology solutions for global healthcare advancement.